Matthew L. Posard Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Matthew L. Posard sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, August 12th. The shares were sold at an average price of $55.72, for a total transaction of $557,200.00. Following the completion of the transaction, the director now owns 89,755 shares in the company, valued at approximately $5,001,148.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Halozyme Therapeutics Stock Up 2.5 %

Shares of HALO stock traded up $1.42 on Wednesday, hitting $57.41. The stock had a trading volume of 2,305,037 shares, compared to its average volume of 1,254,258. The stock’s 50 day moving average is $52.98 and its 200-day moving average is $44.56. The firm has a market capitalization of $7.31 billion, a price-to-earnings ratio of 23.72, a P/E/G ratio of 0.56 and a beta of 1.27. Halozyme Therapeutics, Inc. has a 52-week low of $32.83 and a 52-week high of $58.58. The company has a debt-to-equity ratio of 8.44, a quick ratio of 5.36 and a current ratio of 6.64.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. The company had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. During the same period in the prior year, the company posted $0.68 EPS. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current year.

Wall Street Analyst Weigh In

HALO has been the topic of a number of research analyst reports. Piper Sandler cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the company from $48.00 to $51.00 in a report on Friday, June 7th. TD Cowen lifted their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Wells Fargo & Company increased their target price on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday, June 7th. The Goldman Sachs Group lifted their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $65.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and an average target price of $59.44.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds have recently bought and sold shares of HALO. Rise Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the 1st quarter valued at approximately $25,000. Whittier Trust Co. bought a new position in Halozyme Therapeutics during the 1st quarter valued at $27,000. GAMMA Investing LLC boosted its stake in Halozyme Therapeutics by 96.6% during the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 254 shares during the last quarter. International Assets Investment Management LLC acquired a new position in Halozyme Therapeutics during the 2nd quarter worth $33,000. Finally, Principal Securities Inc. bought a new stake in shares of Halozyme Therapeutics in the 4th quarter worth about $34,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.